Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1209 vs Pertuzumab in HER2+ Breast Cancer
NCT04629846Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of QL1209 in breast cancer (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoint: Total Pathologic Complete Response rate. Started Nov 2020; status: completed.
02
Drugs
QL1209
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04629846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629846.